Loading…
Impact of a treatment escalation/limitation plan on non-beneficial interventions and harms in patients during their last admission before in-hospital death, using the Structured Judgment Review Method
ObjectivesTo assess the effect of using a treatment escalation/limitation plan (TELP) on the frequency of harms in 300 patients who died following admission to hospital.DesignA retrospective case note review of 300 unselected, consecutive deaths comprising: (1) patients with a TELP in addition to a...
Saved in:
Published in: | BMJ open 2018-10, Vol.8 (10), p.e024264-e024264 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ObjectivesTo assess the effect of using a treatment escalation/limitation plan (TELP) on the frequency of harms in 300 patients who died following admission to hospital.DesignA retrospective case note review of 300 unselected, consecutive deaths comprising: (1) patients with a TELP in addition to a do-not-attempt cardiopulmonary resuscitation order (DNACPR); (2) those with DNACPR only; and (3) those with neither. Patient deaths were classified retrospectively as ‘expected’ or ‘unexpected’ using the Gold Standard Framework Prognostic Indicator Guidance.SettingMedical, surgical and intensive care units of a district general hospital.OutcomesThe primary outcome was the between-group difference in rates of harms, non-beneficial interventions (NBIs) and clinical ‘problems’ identified using the Structured Judgement Review Method.Results289 case records were evaluable. 155 had a TELP and DNACPR (54%); 113 had DNACPR only (39%); 21 had neither (7%). 247 deaths (86%) were ‘expected’. Among patients with ‘expected’ deaths and using the TELP/DNACPR as controls (incidence rate ratio (IRR)=1.00), the IRRs were: for harms, 2.99 (DNACPR only) and 4.00 (neither TELP nor DNACPR) (p |
---|---|
ISSN: | 2044-6055 2044-6055 |
DOI: | 10.1136/bmjopen-2018-024264 |